7-[1-(3-Amino-propyl)-1H-indol-3-yl]-1,5-dihydro-1,2,5,8-tetraaza-cyclopenta[b]naphthalen-6-one acetic acid salt | 243838-68-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-[1-(3-Amino-propyl)-1H-indol-3-yl]-1,5-dihydro-1,2,5,8-tetraaza-cyclopenta[b]naphthalen-6-one acetic acid salt
• 英文别名: Acetic acid;7-[1-(3-aminopropyl)indol-3-yl]-1,5-dihydropyrazolo[3,4-g]quinoxalin-6-one
• CAS: 243838-68-8
• 化学式: C₂H₄O₂*C₂₀H₁₈N₆O
• 分子量: 418.455
• InChiKey: KJUCKSNFALTBLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.86
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE L'ANGIOGENESE
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000047212A1

  公开（公告）日：2000-08-17

  The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C¿1-3?alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR?3R4¿ (wherein R?3 and R4¿, which may be the same or different, each represents hydrogen or C¿1-3?alkyl), or R?5X1¿- (wherein X?1 and R5¿ are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C¿1-4?alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R?56X10¿ (wherein X?10 and R56¿ are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及使用式(I)的化合物，其中环C是一个含有1-3个杂原子（独立选择自O、N和S）的8、9、10、12或13元的双环或三环基团；Z是-O-、-NH-、-S-、-CH2-或直接键；n为0-5；m为0-3；R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、-NR3R4（其中R3和R4，可能相同或不同，每个代表氢或C1-3烷基），或R5X1-（其中X1和R5如上定义）；R1代表氢、氧代、卤代、羟基、C1-4烷氧基、C1-4烷基、C1-4烷氧甲基、C1-4烷酰基、C1-4卤代烷基、氰基、氨基、C2-5烯基、C2-5炔基、C1-3烷酰氧基、硝基、C1-4烷酰胺基、C1-4烷氧羰基、C1-4烷基硫基、C1-4烷基亚砜基、C1-4烷基磺酰基、氨基甲酰基、N-C1-4烷基氨基甲酰基、N,N-二(C1-4烷基)氨基甲酰基、氨基磺酰基、N-C1-4烷基氨基磺酰基、N,N-二(C1-4烷基)氨基磺酰基、N-(C1-4烷基磺酰基)氨基、N-(C1-4烷基磺酰基)-N-(C1-4烷基)氨基、N,N-二(C1-4烷基磺酰基)氨基、与两个环C碳原子连接的C3-7烷基链、C1-4烷酰胺基C1-4烷基、羧基或R56X10基团（其中X10和R56如上定义）；以及其盐，在制备用于在温血动物中产生抗血管生成和/或血管通透性降低效应的药物中使用，制备这种化合物的过程，包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物和式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的效果，这是治疗包括癌症和类风湿性关节炎在内的许多疾病状态的有价值的属性。
• NEW COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1071683A1

  公开（公告）日：2001-01-31
• QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1154774A1

  公开（公告）日：2001-11-21
• US6458792B1
  申请人：——

  公开号：US6458792B1

  公开（公告）日：2002-10-01
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO1999046264A1

  公开（公告）日：1999-09-16

  (EN) The present invention provides inhibitors of protein kinase C, of formula (I), wherein: one of: R1 and R2, R2 and R3 or R3 and R4, together form a 5 or 6 membered ring and the two groups of R1, R2, R3 and R4 not forming a ring, are H; and salts thereof, formulations comprising said inhibitors of protein kinase C of formula (I), processes for preparation thereof and use thereof in the manufacture of a medicament for the treatment of inflammatory, immunological, bronchopulmonary, cardiovascular, oncological or CNS-degenerative disorders.(FR) La présente invention concerne des inhibiteurs de la protéine kinase C de formule (I), dans laquelle un des groupes R1 et R2, R2 et R3, ou R3 et R4 forment ensemble un cycle à 5 ou 6 chaînons, et dans laquelle les deux groupes de R1, R2, R3, et R4 ne formant pas de cycle représentent H. L'invention concerne également leurs sels, des formulations comprenant lesdits inhibiteurs de la protéine kinase C de formule (I), leurs procédés de préparation et leur utilisation dans la production d'un médicament destiné au traitement de troubles inflammatoires, immunologiques, broncho-pulmonaires, cardio-vasculaires ou oncologiques, ou de maladies dégénératives du SNC.